5778-86-9

Usage

Uses

Used in Pharmaceutical Industry:
11-AMINO-7,8,9,10-TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE is used as a key intermediate in the synthesis of pharmaceuticals for its ability to contribute to the development of new drug candidates. Its unique structure and potential pharmacological activities make it a promising component in the creation of innovative therapeutic agents.
Used in Organic Synthesis:
In the field of organic synthesis, 11-AMINO-7,8,9,10-TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE is employed as a versatile building block for the preparation of a variety of biologically active molecules. Its structural features allow for the formation of diverse chemical entities with potential applications in medicine and other fields.
Used in Drug Development:
11-AMINO-7,8,9,10-TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE is utilized in drug development as a valuable intermediate due to its potential to enhance the pharmacological properties of new drug candidates. Its incorporation into molecular structures can lead to the discovery of novel therapeutic agents with improved efficacy and selectivity.
Used in Research and Development:
In the research and development sector, 11-AMINO-7,8,9,10-TETRAHYDRO-6H-CYCLOHEPTA[B]QUINOLINE is used as a chemical probe to study its potential applications in the treatment of various diseases and disorders. Its structural features and biological activities make it an interesting subject for scientific investigation, potentially leading to breakthroughs in medical treatments.

InChI:InChI=1/C14H16N2/c15-14-10-6-2-1-3-8-12(10)16-13-9-5-4-7-11(13)14/h4-5,7,9H,1-3,6,8H2,(H2,15,16)

Upstream product

• 1885-29-6 anthranilic acid nitrile 
• 502-42-1 cycloheptanone 

Downstream Products

• 108154-83-2 4-n-Hexylamino-2,3-pentamethylenequinoline hydrochloride 
• 28869-39-8 4-n-Butylamino-2,3-pentamethylenequinoline hydrochloride 

Relevant academic research and scientific papers

Design, Synthesis and Biological Evaluation of New Cycloalkyl Fused Quinolines Tethered to Isatin Schiff Bases as Cholinesterase Inhibitors

Aims and Objective: Alzheimer’s disease is now a most prevalent neurodegenerative disease of central nervous system leading to dementia in elderly population. Numerous pathological changes have been associated in the progression of Alzheimer’s disease. On

Sulfuric acid-modified PEG-6000 (PEG-OSO3H): An efficient, bio-degradable and reusable polymeric catalyst for the solvent-free synthesis of poly-substituted quinolines under microwave irradiation

Sulfuric acid-modified polyethylene glycol 6000 (PEG-OSO3H) is applied as an efficient and eco-friendly polymeric catalyst for Friedlaender synthesis of poly-substituted quinolines from 2-aminoaryl ketones (or anthranilonitrile) and carbonyl compounds possessing a reactive methylene group under microwave irradiation and solvent-free conditions. The reactions are completed in short times, and the products are obtained in good to excellent yields. The Royal Society of Chemistry.

Novel tacrine analogues for potential use against Alzheimer's disease: Potent and selective acetylcholinesterase inhibitors and 5-HT uptake inhibitors

Several novel analogues of tactine have been synthesized and tested for their ability to inhibit acetylcholinesterase, butyrylcholinesterase, and neuronal uptake of 5-HT (serotonin) and noradrenaline. Changes in the size of the carbocyclic ring of tactine produced modest potency against cholinesterase enzymes. Addition of a fourth ring resulted in compounds with marked selectivity for acetylcholinesterase (AChE) over butyrylcholinesterase [BChE): e.g. 6-amino-4,5-benzo-5H-cyclopenta[1,2-b]-quinoline (14a) had an IC50 of 0.35μM against AChE and 3.1 μM against BChE. Some tetracyclic compounds are 100-400 times more active than tacrine as inhibitors of neuronal uptake of serotonin, in particular 13-amino-6,7-dihydro-5H- benzo[3,4]cyclohepta[1,2-b]quinoline (18), which had an IC50 of 20 nM. These compounds would be expected to facilitate both cholinergic and monoaminergic transmission. They should be worth investigating in models of memory impairment.